Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: Predictors and outcomes of nonadherence

European Journal of Preventive Cardiology

Volumn 17, Issue 5, 2010, Pages 576-581

  Bauer, Timm ^a   Gitt, Anselm K ^a,b   Jünger, Claus ^b   Zahn, Ralf ^a   Koeth, Oliver ^a   Towae, Frank ^a   Schwarz, Arne K ^a   Bestehorn, Kurt ^c   Senges, Jochen ^b   Zeymer, Uwe ^a,b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

acute myocardial infarction; clinical practice; comorbidity; guideline adherence; mortality; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SARTAN DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; ODDS RATIO; PATIENT COMPLIANCE; PATIENT DISCHARGE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957803601     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328338e5da     Document Type: Article

References (31)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R etal; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
2. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) Study. Curr Med Res Opin 2002; 18: 220–228.
3. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N EnglJ Med 1998; 339: 1349–1357.
4. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H etal; Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454–1470.
5. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H etal; Task ForceOn Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–1362.
6. Mehta SR, Yusuf S. Short-and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003; 41 (4 Suppl S):79S–88S.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. For the TNT Study Group. N Engl J Med 1996; 335: 1001–1009.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383–1389.
9. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–2945.
10. Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med 2008; 23: 216–218.
11. Fonarow GC, French WJ, Frederick PD. Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998–2006. Am Heart J 2009; 157: 185–194.
12. Koenig W, Löwel H, Lewis M, Hörmann A. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985–1993. Eur Heart J 1996; 17: 1199–1206.
13. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.
14. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177–186.
15. Reiner Z, Mihatov S, Milicić D, Bergovec M, Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehabil 2006; 13: 646–654.
16. Rogers AM, Ramanath VS, Grzybowski M, Riba AL, Jani SM, Mehta R etal; American College of Cardiology Foundation Bethesda, MD. The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 2007; 154: 461–469.
17. Rockson SG, deGoma EM, Fonarow GC. Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. Cardiovasc Drugs Ther 2007; 21: 375–388.
18. Salomaa V, Pääkkönen R, Hämäläinen H, Niemi M, Klaukka T. Use of secondary preventive medications after the first attack of acute coronary syndrome. Eur J Cardiovasc Prev Rehabil 2007; 14: 386–391.
19. Tuppin P, Neumann A, Danchin N, Weill A, Ricordeau P, de Peretti C, et al Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Arch Cardiovasc Dis 2009; 102: 279–292.
20. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al Guidelines for the diagnosis and treatment of non-ST -segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598–1660.
21. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
22. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005; 4: CD003566.
23. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97: 1094–1101.
24. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769–1776.
25. Aronow WS. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol Med Sci 2004; 59: 172–177.
26. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140.
27. Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006; 4: CD006257.
28. Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events: September 14–15, 1995. J Am Coll Cardiol 1996; 27: 957–1047.
29. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Colesterol lowering in the elderly population. Arch Intern Med 1999; 159: 1670–1678.
30. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV Jr., Foody JM etal; for the CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with Non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1479–1487.
31. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, et al Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006; 27: 789–795.